Transaction Details
The transaction consideration will be comprised entirely of stock, where Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26 million. Net cash is total cash, cash equivalents, and short-term investments, adjusted by certain factors including debt, which includes term debt with an outstanding principal of $15 million, and other liabilities, as defined in the merger agreement. The stock value will be based on Equillium's 10-day volume weighted average closing price calculated ten trading days prior to closing, subject to a share price collar ranging from $2.70 to $4.50. In addition, Equillium has agreed to terms on an amended debt facility with Metacrine's current lender, K2 HealthVentures LLC, whereby Equillium would assume Metacrine's existing loan with an outstanding principal balance of $15 million, along with potential access to an additional $10 million of committed debt capital. Concurrent with the transaction closing, Equillium intends to retire its existing debt facility with Oxford Finance LLC and SVB, which currently has an outstanding principal balance of $10 million. After paying off its existing debt facility, Equillium expects to add an estimated $33 million of cash to its balance sheet at closing. Equillium is not planning to retain any current Metacrine employees and expects to assume minimal operating expenses while maintaining sole discretion over the timing and extent of advancing development of the Metacrine programs. The acquisition is anticipated to close late 2022 pending approval from both Equillium and Metacrine shareholders, Metacrine having minimum net cash of $23 million, and other customary closing conditions.
Preston Klassen, M.D., MHS, has served as president and chief executive officer and as a member of the board of directors of Metacrine since June 2020. From March 2017 to June 2020, Dr. Klassen served as executive vice president, head of research and development and chief medical officer of Arena Pharmaceuticals, Inc. From June 2016 to March 2017, he was chief medical officer of Laboratoris Sanifit S.L., and from November 2009 to May 2016, was executive vice president, head of global development at Orexigen Therapeutics, Inc. Dr. Klassen also held several positions of increasing responsibility at Amgen Inc., including therapeutic area head for nephrology. Before joining Amgen, he was a faculty member in the Division of Nephrology at Duke University Medical Center. Dr. Klassen received his medical degree from the University of Nebraska College of Medicine, completed his residency in internal medicine, fellowship in nephrology, and Master of Health Sciences degree at Duke University and holds a B.S. in Chemistry from Central University of Iowa.
取引の詳細
取引対価格は完全に株式からなり,Equilliumは株を発行し,その価値は取引時に交付された現金純価値より25%割増し,約2600万ドルと見積もられる.純現金は、現金、現金等価物、および短期投資の総額であり、1500万ドルの未償還元金の定期債務と、合併協定で定義された他の債務を含む債務を含むいくつかの要因によって調整される。株価は、Equilliumが終値の10取引日前に計算した10日の出来高加重平均終値に基づき、株価上限は2.70ドルから4.50ドルとなる。さらに、EquilliumはMetacineの現在の融資者K 2 HealthVentures LLCと修正された債務手配条項に同意し、この条項によると、Equilliumは1500万ドルの未返済元金残高でMetacineの既存の融資を負担し、追加の1000万ドルの約束債務資本を得ることができる。取引完了と同時に、Equilliumはオックスフォード金融有限責任会社とSVBとの既存債務手配を解約しようとしており、この2社の現在の未返済元金残高は1000万ドルである。既存の債務手配を返済した後、Equilliumは取引完了時に、その貸借対照表に約3300万ドルの現金を増加させると予想される。Equilliumは既存のMetacine従業員を保持しようとせず,Metacine計画開発を進めるタイミングと程度に対する唯一の検討権を保ちながら,最低限の運営費用を負担する予定である。今回の買収は2022年末に完了する予定であり,EquilliumとMetacine株主の承認を待ち,Metacineの最低純現金は2300万ドル,その他の慣用的な完成条件である。
プレストン·クラソン、医学博士、医学修士、2020年6月以来総裁とMetacineの最高経営責任者と取締役会のメンバーを務めてきた。2017年3月から2020年6月まで、クラセン博士はアリーナPharmPharmticals Inc.研究開発担当兼首席医療官執行副総裁を務め、2016年6月から2017年3月までSanifit S.L.実験室首席医療官を務め、2009年11月から2016年5月まで、オレシガン治療会社の全世界発展主管執行副総裁を務めた。クラソン博士は安進で腎臓内科治療区担当者を含む多くの責任が増加している職を務めている。安進に入る前、彼はデューク大学医学センター腎臓科の教員だった。クラソン博士はネブラスカ州大学医学院で医学学位を取得し、デューク大学で内科入院医師、腎臓病研究員と健康科学修士号を完成し、アイオワ州中央大学で化学学士号を取得した。